Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 1
1977 3
1978 12
1979 9
1980 4
1981 8
1982 7
1983 15
1984 16
1985 17
1986 21
1987 23
1988 28
1989 29
1990 27
1991 36
1992 39
1993 31
1994 43
1995 39
1996 49
1997 39
1998 35
1999 29
2000 30
2001 15
2002 10
2003 9
2004 11
2005 8
2006 12
2007 3
2008 4
2009 3
2010 5
2011 4
2012 5
2013 3
2014 2
2015 3
2016 4
2017 5
2018 3
2019 4
2020 1
2021 6
2022 9
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Results by year

Filters applied: . Clear all
Page 1
Precision surgery and genitourinary cancers.
Autorino R, Porpiglia F, Dasgupta P, Rassweiler J, Catto JW, Hampton LJ, Lima E, Mirone V, Derweesh IH, Debruyne FMJ. Autorino R, et al. Among authors: debruyne fmj. Eur J Surg Oncol. 2017 May;43(5):893-908. doi: 10.1016/j.ejso.2017.02.005. Epub 2017 Feb 20. Eur J Surg Oncol. 2017. PMID: 28254473 Review.
Legends in urology.
Debruyne FM. Debruyne FM. Can J Urol. 2015 Apr;22(2):7678-80. Can J Urol. 2015. PMID: 25891329 Free article. No abstract available.
Epidemiology of prostate cancer.
Dijkman GA, Debruyne FM. Dijkman GA, et al. Among authors: debruyne fm. Eur Urol. 1996;30(3):281-95. doi: 10.1159/000474185. Eur Urol. 1996. PMID: 8931959 Review.
Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Gómez Rivas J, Carrion DM, Alvarez-Maestro M, Cathelineau X, Sanchez-Salas R, Di Lorenzo G, Di Maio M, Paul A, Martinez-Piñeiro L, Sartor O, Saad F, Debruyne F. Gómez Rivas J, et al. Among authors: debruyne f. Minerva Urol Nefrol. 2019 Oct;71(5):445-456. doi: 10.23736/S0393-2249.19.03420-9. Epub 2019 Jul 25. Minerva Urol Nefrol. 2019. PMID: 31353876 Free article. Review.
Hormonal therapy of prostate cancer.
Debruyne F. Debruyne F. Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):4-9. doi: 10.1053/suro.2002.35051. Semin Urol Oncol. 2002. PMID: 12198632 Review.
Alpha blockers: are all created equal?
Debruyne FM. Debruyne FM. Urology. 2000 Nov 1;56(5 Suppl 1):20-2. doi: 10.1016/s0090-4295(00)00744-5. Urology. 2000. PMID: 11074198 Review.
Oncogene expression in prostate cancer.
Schalken JA, Bussemakers MJ, Debruyne FM. Schalken JA, et al. Among authors: debruyne fm. Prog Clin Biol Res. 1990;357:97-105. Prog Clin Biol Res. 1990. PMID: 2217484 Review.
Role of testosterone in managing advanced prostate cancer.
Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Rove KO, et al. Among authors: debruyne fm. Urology. 2012 Oct;80(4):754-62. doi: 10.1016/j.urology.2012.05.006. Epub 2012 Jul 13. Urology. 2012. PMID: 22795376 Review.
716 results